INOVIO PHARMACEUTICALS, INC. Files 8-K
Ticker: INO · Form: 8-K · Filed: Apr 6, 2026 · CIK: 0001055726
| Field | Detail |
|---|---|
| Company | Inovio Pharmaceuticals, INC. (INO) |
| Form Type | 8-K |
| Filed Date | Apr 6, 2026 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001, $1.40, $1.399, $16 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
INOVIO PHARMACEUTICALS, INC. signed a new deal, check the 8-K for details.
AI Summary
On April 2, 2026, INOVIO PHARMACEUTICALS, INC. entered into a material definitive agreement. The filing also includes other events and financial statements/exhibits related to this report.
Why It Matters
This 8-K filing indicates a significant new agreement for INOVIO PHARMACEUTICALS, INC., which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.
Key Players & Entities
- INOVIO PHARMACEUTICALS, INC. (company) — Filer of the 8-K
- 0001055726 (company) — CIK number for INOVIO PHARMACEUTICALS, INC.
- 2026-04-02 (date) — Period of report and date of material definitive agreement
- 2026-04-06 (date) — Filing date and acceptance date of the 8-K
FAQ
What is the nature of the material definitive agreement entered into by INOVIO PHARMACEUTICALS, INC. on April 2, 2026?
The filing indicates Item 1.01: Entry into a Material Definitive Agreement, but the specific details of the agreement are not provided in the summary text.
What other events are reported in this 8-K filing?
The filing includes Item 8.01: Other Events, alongside the material definitive agreement.
Are financial statements included in this filing?
Yes, Item 9.01: Financial Statements and Exhibits indicates that financial statements and exhibits are part of this filing.
What is the CIK number for INOVIO PHARMACEUTICALS, INC.?
The CIK number for INOVIO PHARMACEUTICALS, INC. is 0001055726.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on April 6, 2026.
Filing Stats: 1,723 words · 7 min read · ~6 pages · Grade level 11.8 · Accepted 2026-04-06 07:03:10
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark
- $1.40 — n lieu thereof) at an exercise price of $1.40 per share of common stock (or $1.399 pe
- $1.399 — of $1.40 per share of common stock (or $1.399 per Pre-Funded Warrant) (the " Series A
- $16 m — fering are expected to be approximately $16 million, after deducting the underwriting
Filing Documents
- d137120d8k.htm (8-K) — 38KB
- d137120dex11.htm (EX-1.1) — 200KB
- d137120dex41.htm (EX-4.1) — 77KB
- d137120dex42.htm (EX-4.2) — 84KB
- d137120dex43.htm (EX-4.3) — 83KB
- d137120dex51.htm (EX-5.1) — 16KB
- d137120dex991.htm (EX-99.1) — 7KB
- d137120dex992.htm (EX-99.2) — 8KB
- g137120g0403033514346.jpg (GRAPHIC) — 4KB
- g137120g0403034717551.jpg (GRAPHIC) — 6KB
- g137120g0403034900874.jpg (GRAPHIC) — 6KB
- 0001193125-26-142885.txt ( ) — 789KB
- ino-20260402.xsd (EX-101.SCH) — 3KB
- ino-20260402_lab.xml (EX-101.LAB) — 18KB
- ino-20260402_pre.xml (EX-101.PRE) — 11KB
- d137120d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," "plans," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the Offering, such as the expected net proceeds and anticipated closing date. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company's business are described in detail in its SEC filings, including in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, which is available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 1.1 Underwriting Agreement, dated April 2, 2026, by and between Inovio Pharmaceuticals, Inc. and Piper Sandler & Co. 4.1 Form of Pre-Funded Warrant. 4.2 Form of Series A Warrant. 4.3 Form of Series B Warrant. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 99.1 Press Release. 99.2 Press Release. 104 Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: April 6, 2026 /s/ Peter Kies Peter Kies Chief Financial Officer